- Conditions
- Alzheimer Disease
- Interventions
- Not listed
- Lead sponsor
- MaxWell Clinic, PLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Brentwood, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 1,932
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Health Behavior
- Interventions
- Stress Management Control, Adapted MBC2 Program
- Behavioral
- Lead sponsor
- Nancy Schoenberg
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Benham, Kentucky
- Conditions
- Alzheimer Disease, Progressive Posterior Cortical Dysfunction (PPCD)
- Interventions
- F 18 T807
- Drug
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer's Disease
- Interventions
- ABT-354, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Overland Park, Kansas
- Conditions
- Alzheimer's Disease, Huntington's Disease
- Interventions
- Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- Alzheimer Disease
- Interventions
- Lithia water, Transcranial Magnetic stimulation
- Dietary Supplement · Device
- Lead sponsor
- American Society Of Thermalism And Climatology Inc
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
- Interventions
- Biomarker Data Collection
- Other
- Lead sponsor
- GAP Innovations, PBC
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,002 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 16
- States / cities
- Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
- Conditions
- Alzheimer Disease
- Interventions
- PET-MR Scan, PiB
- Procedure · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease
- Interventions
- [11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
- Drug
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer Disease
- Interventions
- Donanemab, Usual Care
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 6,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 1
- States / cities
- Huntsville, Alabama
- Conditions
- Alzheimer's Disease, Psychomotor Agitation
- Interventions
- Escitalopram (Lexapro)
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 61 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 3
- States / cities
- Fairport, New York • Rochester, New York
- Conditions
- Alzheimer Disease, Aging, Aged, 80 and Over, Biomarkers, Brain, Case-Control Studies, Cognitive Dysfunction, Neuropsychological Tests
- Interventions
- none, observational study
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Amnestic Mild Cognitive Disorder
- Interventions
- Diagnostic Disclosure Protocol, Biomarker Disclosure Protocol
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Alzheimer's Disease
- Interventions
- Posiphen, Placebo
- Drug
- Lead sponsor
- Annovis Bio Inc.
- Industry
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- La Jolla, California • Indianapolis, Indiana • Baltimore, Maryland + 3 more
- Conditions
- Early Alzheimer's Disease
- Interventions
- Lecanemab IV, Placebo, Lecanemab SC
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 112
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 82 more
- Conditions
- Alzheimer Disease
- Interventions
- 18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
- Drug
- Lead sponsor
- Tharick Pascoal
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 822 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease
- Interventions
- Structured External Memory Aid Treatment (SEMAT)
- Behavioral
- Lead sponsor
- University of Delaware
- Other
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Alzheimer's Disease
- Interventions
- MSDC-0160, Placebo
- Drug
- Lead sponsor
- Metabolic Solutions Development Company
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hepatitis C
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease
- Interventions
- Crenezumab dose level 1, Crenezumab dose level 2, Crenezumb dose level 3, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • San Francisco, California • Delray Beach, Florida + 10 more
- Conditions
- Alzheimer's Disease
- Interventions
- Piromelatine 20 mg, Placebo
- Drug
- Lead sponsor
- Neurim Pharmaceuticals Ltd.
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 32
- States / cities
- Costa Mesa, California • Long Beach, California • San Diego, California + 21 more
- Conditions
- Alzheimer's Disease
- Interventions
- AN-1792 also known as AIP-001
- Biological
- Lead sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 11
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 8 more
- Conditions
- Alzheimer Disease
- Interventions
- Disclosure of APOE genotype
- Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 40 Years to 64 Years
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer's Disease
- Interventions
- Flortaucipir F18, Brain PET scan
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Newport Beach, California • New Haven, Connecticut